CE
CELZ.US Creative Medical Technology Holdings Inc
- Market cap
- USD 4.01M
- P/E
- -
- P/B
- 0.54x
- ROE
- -107.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CELZ.US undervalued?
Graham numberThe Graham number of Creative Medical Technology Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Creative Medical Technology Holdings Inc fundamental analysis
No fundamental analysis for Creative Medical Technology Holdings Inc yet.
Creative Medical Technology Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100),…
Full company profileCreative Medical Technology Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Creative Medical Technology Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 4.80K | 124K | 166K | 165K | 87.8K | 88.6K | 9.00K | 11.0K | 6.00K | 0.00 |
| Gross Profit | -766K | -3.20K | 54.0K | 120K | 114K | 39.8K | 60.1K | 5.40K | 6.60K | 3.81K | -69.0K |
| Operating Income | -766K | -1.18M | -1.11M | -1.13M | -1.11M | -3.13M | -10.2M | -5.62M | -5.74M | -6.14M | -7.66M |
| EBITDA | -750K | -1.16M | -1.09M | -6.56M | -35.0M | 23.6M | -10.1M | -5.19M | -5.38M | -6.02M | -7.58M |
| Net Income | -766K | -2.66M | -13.7M | -8.48M | -36.3M | 19.2M | -10.1M | -5.29M | -5.49M | -6.00M | -7.45M |
| EPS | -5,472 | -17,380 | -11,351 | -4,102 | -627 | 59 | -9.28 | -3.76 | -3.71 | -2.52 | -1.12 |
| Balance Sheet | |||||||||||
| Total Assets | 323K | 203K | 477K | 531K | 718K | 11.3M | 19.2M | 10.7M | 6.67M | 7.81M | 7.28M |
| Total Liabilities | 480K | 2.44M | 4.47M | 8.60M | 40.5M | 1.05M | 3.32M | 371K | 328K | 285K | 293K |
| Shareholders' Equity | -158K | -2.24M | -3.99M | -8.07M | -39.8M | 10.2M | 15.9M | 10.3M | 6.34M | 7.51M | 6.95M |
| Cash & Short-term Investments | 222K | 13.7K | 304K | 88.6K | 98.0K | 10.7M | 18.4M | 9.99M | 5.94M | 7.21M | 6.85M |
| Total Debt | 125K | 513K | 682K | 1.06M | 789K | 14.2K | 14.2K | 14.2K | 14.2K | 14.2K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -445K | -890K | -1.05M | -1.21M | -435K | -2.22M | -7.80M | -8.03M | -5.30M | -5.86M | -5.95M |
| Capital Expenditure | 10.0K | 0.00 | 0.00 | 3.00 | 250K | 0.00 | 4.00 | 100K | 200K | 5.00 | 167K |
| Free Cash Flow | -455K | -890K | -1.05M | -1.21M | -685K | -2.22M | -7.80M | -8.13M | -5.30M | -5.86M | -5.95M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | 188.0% | -63.9% | -51.1% | -86.6% | -79.8% | -107.1% |
| ROA | -237.5% | -1,309.0% | -2,861.9% | -1,598.3% | -5,060.8% | 170.5% | -52.9% | -49.3% | -82.4% | -76.8% | -102.3% |
| Net Profit Margin | - | -55,398.1% | -10,977.2% | -5,126.1% | -22,082.2% | 21,892.8% | -11,449.3% | -58,739.7% | -49,940.7% | -99,916.8% | - |
| Debt to Equity | - | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Creative Medical Technology Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 4.78M | 15 | 24.9% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jun 12, 2023.
Who owns Creative Medical Technology Holdings Inc
- Insiders 15.70%
- Institutions 5.89%
- Public & others 78.41%
- Shares outstanding 7.60M
- Free float 6.56M
Top funds holding CELZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 18.7K | 0.25% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 3.97K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.55K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding CELZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Hudson Bay Capital Management LP | 135K | 1.78% | 0.00% | Jun 2026 |
| Anson Funds Management LP | 106K | 1.39% | 0.00% | Jun 2026 |
| Armistice Capital, LLC | 42.0K | 0.55% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 26.6K | 0.35% | +86.25% | Jun 2026 |
| Geode Capital Management, LLC | 25.8K | 0.34% | -32.62% | Jun 2026 |
| Vanguard Capital Management, LLC | 20.4K | 0.27% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 5.52K | 0.07% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 4.85K | 0.06% | +131.98% | Jun 2026 |
| Global Retirement Partners, LLC. | 4.12K | 0.05% | -47.99% | Jun 2026 |
| UBS Group AG | 2.06K | 0.03% | +206,000.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 514.00 | 0.01% | -3.75% | Jun 2026 |
| Barclays PLC | 54.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 43.00 | 0.00% | +4,200.00% | Jun 2026 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| FMR Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Creative Medical Technology Holdings Inc company profile
- Company name
- Creative Medical Technology Holdings Inc
- Ticker
- CELZ.US
- Exchange
- USA Stocks
- Listed since
- Nov 6, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 211 East Osborn Road, Phoenix, AZ, United States, 85012
- Phone
- 480 399 2822
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Creative Medical Technology Holdings Inc management
2- Mr. Timothy WarbingtonCo-Founder, Chairman, President & CEO · born 1962
- Mr. Donald F. Dickerson MBASenior VP, CFO & Director · born 1965